Head-To-Head Contrast: Inozyme Pharma (NASDAQ:INZY) and Oncternal Therapeutics (NASDAQ:ONCT)

Oncternal Therapeutics (NASDAQ:ONCT) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Oncternal Therapeutics and Inozyme Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncternal Therapeutics	-1,599.95%	-177.58%	-131.30%
Inozyme Pharma	N/A	-88.42%	-57.02%

Institutional and Insider Ownership

16.0% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are owned by institutional investors. 11.2% of Oncternal Therapeutics shares are owned by company insiders. Comparatively, 12.2% of Inozyme Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Oncternal Therapeutics and Inozyme Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncternal Therapeutics	$790,000.00	1.97	-$39.48 million	($11.69)	-0.05
Inozyme Pharma	N/A	N/A	-$71.17 million	($1.69)	-2.34

Oncternal Therapeutics has higher revenue and earnings than Inozyme Pharma. Inozyme Pharma is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Oncternal Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Oncternal Therapeutics and Inozyme Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncternal Therapeutics	0	3	1	0	2.25
Inozyme Pharma	0	5	4	0	2.44

Oncternal Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 1,798.97%. Inozyme Pharma has a consensus price target of $11.75, suggesting a potential upside of 197.47%. Given Oncternal Therapeutics’ higher probable upside, equities analysts clearly believe Oncternal Therapeutics is more favorable than Inozyme Pharma.

Summary

Inozyme Pharma beats Oncternal Therapeutics on 9 of the 13 factors compared between the two stocks.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

About Inozyme Pharma

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.